BlueSky Immunotherapies GmbH
🇦🇹Austria
Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Phase 1
Recruiting
- Conditions
- Oropharyngeal Squamous Cell Carcinoma (SCC)
- Interventions
- First Posted Date
- 2024-09-10
- Last Posted Date
- 2024-09-10
- Lead Sponsor
- BlueSky Immunotherapies GmbH
- Target Recruit Count
- 12
- Registration Number
- NCT06589609
- Locations
- 🇦🇹
Medical University Vienna, Vienna, Austria
Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
Phase 1
Recruiting
- Conditions
- HPV InfectionHPV-Related Cervical Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- BlueSky Immunotherapies GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT05829629
- Locations
- 🇸🇰
Univerzitná nemocnica Bratislava, Bratislava, Slovakia
BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
Completed
- Conditions
- Safety IssuesHPV Infection
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- BlueSky Immunotherapies GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT04528407
- Locations
- 🇦🇹
University of Vienna, Vienna, Austria
Study of FluBHPVE6E7 in HPV-16 Infected Women
Phase 1
Completed
- Conditions
- HPV Infection
- Interventions
- Biological: FluBHPVE6E7
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- BlueSky Immunotherapies GmbH
- Target Recruit Count
- 28
- Registration Number
- NCT04490512
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
© Copyright 2025. All Rights Reserved by MedPath